AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1 to 8 (canceled).

Claim 9 (original). A compound of Formula IV

$$\mathbb{R}^{7}$$
 $(CH_2)_n$
 O
 O
 $(CH_2)_n$
 \mathbb{R}^{8}
 \mathbb{R}^{9}
 \mathbb{R}^{9}

or a pharmaceutically acceptable salt thereof,

wherein Each n independently is an integer of from 0 to 6;

 R^2 is hydrogen, halo, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, NO_2 , NR^4R^5 , CN, or CF_3 ; and R^6 , R^7 , R^8 , and R^9

C2-C6 arkyrryr, 1002, 100 'R', C10, or C13, and R', R', R', and R'

independently are hydrogen, halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, nitro, or NH_2 ;

 ${\rm R}^4$ and ${\rm R}^5$ independently are H, C $_1$ -C $_6$ alkyl, C $_2$ -C $_6$ alkenyl, C $_2$ -C $_6$ alkynyl,

 $(CH_2)_n$ aryl, $(CH_2)_n$ cycloalkyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted.

Claim 10 (canceled).

Claim 11 (original). A compound selected from:

- Pyrimidine-4,6-dicarboxylic acid, (4-chloro-benzylamide), [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (4-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carbomethoxy-benzylamide), (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-pyridylmethylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-thiophenemethylamide);
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzooxadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (4-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester;

Pyrimidine-4,6-dicarboxylic acid, bis-(4-chloro-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-[(1,3-benzodioxol-5-ylmethyl)-amide];

Pyrimidine-4,6-dicarboxylic acid, bis-(4-methoxy-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-(3-methoxy-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-(4-carboxy-benzylamide); and

Pyrimidine-4,6-dicarboxylic acid, bis-(4-carbomethoxy-benzylamide).

Claims 12 to 14 (canceled).

Claim 15 (withdrawn). The pharmaceutical composition according to Claim 12, comprising an MMP-13 inhibiting amount of a compound of Formula IV, or a pharmaceutically acceptable salt thereof, A pharmaceutical composition, comprising an MMP-13 inhibiting amount of a compound of Claim 9, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient.

Claims 16 to 21 (canceled).

- Claim 22 (currently amended). A method for treating inflammation, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.
- Claim 23 (currently amended). A method for treating osteoarthritis, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.
- Claim 24 (currently amended). A method for treating rheumatoid arthritis, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.

Claim 25 (canceled).